

Special Issue

Trends in Obesity Research and Anti-Obesity Therapeutics

Message from the Guest Editors

The obese population is increasing rapidly worldwide. In 2016, more than 1.9 billion adults were overweight, of which more than 650 million were obese. Obesity is a main cause of cardiovascular disease, diabetes, musculoskeletal disease, and some types of cancer. The increase in obesity reduces quality of life and increases medical and social costs. In order to solve these problems, the prevention of obesity and the development of effective novel drug treatments are essential. On the other hand, safe and effective surgical and drug treatment methods for obesity have not been established so far. Currently, intensive studies are being conducted for the understanding of the cause and mechanism in developing obesity and the approaches for its prevention and treatment. This Special Issue focuses on the latest research on the identification of molecular targets, nutritional and environmental factors causing obesity, and the development of various pharmacotherapeutics including small molecules, biologics, and cell therapy and their pharmacological, pharmacokinetics and formulation studies.

Guest Editors

Prof. Dr. Han-Joo Maeng

College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea

Prof. Dr. Kwang-Hoon Chun

College of Pharmacy, Gachon University, Incheon 21936, Korea

Deadline for manuscript submissions

closed (30 April 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/100332

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).